project	sample	experiment	run	read_count_as_reported_by_sra	reads_downloaded	proportion_of_reads_reported_by_sra_downloaded	paired_end	sra_misreported_paired_end	mapped_read_count	auc	sharq_beta_tissue	sharq_beta_cell_type	biosample_submission_date	biosample_publication_date	biosample_update_date	avg_read_length	geo_accession	bigwig_file	title	characteristics
SRP040236	SRS576515	SRX493858	SRR1197149	37060612	37060612	1	TRUE	FALSE	33909903	2363972374	umbilical cord	hek	2014-03-17T09:00:51.097	2014-07-01T00:44:28.483	2014-07-01T01:33:34.970	200	GSM1348954	SRR1197149.bw	SKOV3ip1_WT_1	c("cell line: SKOV3ip1", "cell type: ovarian adenocarcinoma", "growth protocol: grown in DMEM/F12 (50/50) medium (Wisent), supplemented with 10 % fetal bovine serum and 2 mM L-glutamine, cells passaged as recommended by ATCC", "treatment: none")
SRP040236	SRS576516	SRX493859	SRR1197150	32859804	32859804	1	TRUE	FALSE	30145122	2106617760	umbilical cord	hek	2014-03-17T09:00:38.673	2014-07-01T00:44:28.357	2014-07-01T01:37:19.520	200	GSM1348955	SRR1197150.bw	SKOV3ip1_WT_2	c("cell line: SKOV3ip1", "cell type: ovarian adenocarcinoma", "growth protocol: grown in DMEM/F12 (50/50) medium (Wisent), supplemented with 10 % fetal bovine serum and 2 mM L-glutamine, cells passaged as recommended by ATCC", "treatment: none")
SRP040236	SRS576517	SRX493860	SRR1197151	46972456	46972456	1	TRUE	FALSE	44307896	3363860971	breast	mcf	2014-03-17T09:00:31.110	2014-07-01T00:44:28.273	2014-07-01T01:37:19.840	200	GSM1348956	SRR1197151.bw	MCF7_WT_1	c("cell line: MCF7", "cell type: breast adenocarcinoma", "growth protocol: grown in EMEM (Wisent) supplemented with 1 mM sodium pyruvate and MEM nonessential amino acid (Wisent), supplemented with 10 % fetal bovine serum and 2 mM L-glutamine, cells passaged as recommended by ATCC", "treatment: none")
SRP040236	SRS576518	SRX493861	SRR1197152	39985848	39985848	1	TRUE	FALSE	38619016	2992126711	breast	mcf	2014-03-17T09:00:21.050	2014-07-01T00:44:28.160	2014-07-01T01:37:20.247	200	GSM1348957	SRR1197152.bw	MCF7_WT_2	c("cell line: MCF7", "cell type: breast adenocarcinoma", "growth protocol: grown in EMEM (Wisent) supplemented with 1 mM sodium pyruvate and MEM nonessential amino acid (Wisent), supplemented with 10 % fetal bovine serum and 2 mM L-glutamine, cells passaged as recommended by ATCC", "treatment: none")
SRP040236	SRS576519	SRX493862	SRR1197153	37944912	37944912	1	TRUE	FALSE	35262850	2658886254	skin	bj	2014-03-17T09:00:18.530	2014-07-01T00:44:28.130	2014-07-01T01:37:20.533	200	GSM1348958	SRR1197153.bw	BJ-Tielf_WT_1	c("cell line: BJ-Tielf", "cell type: immortalized normal skin fibroblast", "growth protocol: grown in alpha-MEM (Wisent), supplemented with 10 % fetal bovine serum and 2 mM L-glutamine, cells passaged as recommended by ATCC", "treatment: none")
SRP040236	SRS576520	SRX493863	SRR1197154	40448636	40448636	1	TRUE	FALSE	36064979	2603798836	skin	bj	2014-03-17T09:00:33.610	2014-07-01T00:44:28.300	2014-07-01T01:37:20.873	200	GSM1348959	SRR1197154.bw	BJ-Tielf_WT_2	c("cell line: BJ-Tielf", "cell type: immortalized normal skin fibroblast", "growth protocol: grown in alpha-MEM (Wisent), supplemented with 10 % fetal bovine serum and 2 mM L-glutamine, cells passaged as recommended by ATCC", "treatment: none")
SRP040236	SRS576521	SRX493864	SRR1197155	38836712	38836712	1	TRUE	FALSE	34337146	2455210344	umbilical cord	hek	2014-03-17T09:00:36.270	2014-07-01T00:44:28.330	2014-07-01T01:37:21.240	200	GSM1348960	SRR1197155.bw	INOF_WT_1	c("cell line: INOF", "cell type: immortalized normal ovarian fibroblast", "growth protocol: grown in OSE medium (Wisent) , supplemented with 10 % fetal bovine serum and 2 mM L-glutamine, cells passaged as recommended by ATCC", "treatment: none")
SRP040236	SRS576522	SRX493865	SRR1197156	39469836	39469836	1	TRUE	FALSE	34568311	2447830837	umbilical cord	hek	2014-03-17T09:00:41.240	2014-07-01T00:44:28.380	2014-07-01T01:37:21.630	200	GSM1348961	SRR1197156.bw	INOF_WT_2	c("cell line: INOF", "cell type: immortalized normal ovarian fibroblast", "growth protocol: grown in OSE medium (Wisent) , supplemented with 10 % fetal bovine serum and 2 mM L-glutamine, cells passaged as recommended by ATCC", "treatment: none")
SRP040236	SRS576523	SRX493866	SRR1197157	38365230	38365230	1	TRUE	FALSE	36282335	2595025594	umbilical cord	hek	2014-03-17T09:00:28.580	2014-07-01T00:44:28.250	2014-07-01T01:37:21.970	200	GSM1348962	SRR1197157.bw	SKOV3ip1_LF_1	c("cell line: SKOV3ip1", "cell type: ovarian adenocarcinoma", "growth protocol: grown in DMEM/F12 (50/50) medium (Wisent), supplemented with 10 % fetal bovine serum and 2 mM L-glutamine, cells passaged as recommended by ATCC", "treatment: Lipofectamine 2000 treated")
SRP040236	SRS576524	SRX493867	SRR1197158	38279988	38279988	1	TRUE	FALSE	36166223	2607262428	umbilical cord	hek	2014-03-17T09:00:43.697	2014-07-01T00:44:28.407	2014-07-01T01:37:22.510	200	GSM1348963	SRR1197158.bw	SKOV3ip1_LF_2	c("cell line: SKOV3ip1", "cell type: ovarian adenocarcinoma", "growth protocol: grown in DMEM/F12 (50/50) medium (Wisent), supplemented with 10 % fetal bovine serum and 2 mM L-glutamine, cells passaged as recommended by ATCC", "treatment: Lipofectamine 2000 treated")
SRP040236	SRS576525	SRX493868	SRR1197159	40099214	40099214	1	TRUE	FALSE	37579254	2668484634	umbilical cord	hek	2014-03-17T09:00:23.547	2014-07-01T00:44:28.187	2014-07-01T01:37:22.897	200	GSM1348964	SRR1197159.bw	SKOV3ip1_LF_3	c("cell line: SKOV3ip1", "cell type: ovarian adenocarcinoma", "growth protocol: grown in DMEM/F12 (50/50) medium (Wisent), supplemented with 10 % fetal bovine serum and 2 mM L-glutamine, cells passaged as recommended by ATCC", "treatment: Lipofectamine 2000 treated")
SRP040236	SRS576526	SRX493869	SRR1197160	29936216	29936216	1	TRUE	FALSE	28286338	2134052011	umbilical cord	hek	2014-03-17T09:00:48.577	2014-07-01T00:44:28.457	2014-07-01T01:37:23.807	200	GSM1348965	SRR1197160.bw	SKOV3ip1_NOP58KD_1	c("cell line: SKOV3ip1", "cell type: ovarian adenocarcinoma", "growth protocol: grown in DMEM/F12 (50/50) medium (Wisent), supplemented with 10 % fetal bovine serum and 2 mM L-glutamine, cells passaged as recommended by ATCC", "treatment: Treated with siRNA targeting NOP58 (CUUCUACCGUUCAGAUUCU). Transfection was performed in suspension using Lipofectamine 2000 (Life technologies) according to the manufacturer’s protocol and 20 nM of siRNA (Sigma) for 48 hours.")
SRP040236	SRS576527	SRX493870	SRR1197161	39809340	39809340	1	TRUE	FALSE	37269592	2718173039	umbilical cord	hek	2014-03-17T09:00:26.023	2014-07-01T00:44:28.223	2014-07-01T01:37:24.527	200	GSM1348966	SRR1197161.bw	SKOV3ip1_NOP58KD_2	c("cell line: SKOV3ip1", "cell type: ovarian adenocarcinoma", "growth protocol: grown in DMEM/F12 (50/50) medium (Wisent), supplemented with 10 % fetal bovine serum and 2 mM L-glutamine, cells passaged as recommended by ATCC", "treatment: Treated with siRNA targeting NOP58 (GACAAGUCCCAAACACAAA). Transfection was performed in suspension using Lipofectamine 2000 (Life technologies) according to the manufacturer’s protocol and 20 nM of siRNA (Sigma) for 48 hours.")
SRP040236	SRS576528	SRX493871	SRR1197162	43347716	43347716	1	TRUE	FALSE	40940502	2988810521	umbilical cord	hek	2014-03-17T09:00:15.867	2014-07-01T00:44:28.033	2014-07-01T01:37:24.890	200	GSM1348967	SRR1197162.bw	SKOV3ip1_RBFOX2KD_1	c("cell line: SKOV3ip1", "cell type: ovarian adenocarcinoma", "growth protocol: grown in DMEM/F12 (50/50) medium (Wisent), supplemented with 10 % fetal bovine serum and 2 mM L-glutamine, cells passaged as recommended by ATCC", "treatment: Treated with siRNA targeting RBFOX2 (GAUGGUCACACCAUAUGCA). Transfection was performed in suspension using Lipofectamine 2000 (Life technologies) according to the manufacturer’s protocol and 20 nM of siRNA (Sigma) for 48 hours.")
SRP040236	SRS576529	SRX493872	SRR1197163	39722244	39722244	1	TRUE	FALSE	37542134	2751252283	umbilical cord	hek	2014-03-17T09:00:46.080	2014-07-01T00:44:28.433	2014-07-01T01:37:25.313	200	GSM1348968	SRR1197163.bw	SKOV3ip1_RBFOX2KD_2	c("cell line: SKOV3ip1", "cell type: ovarian adenocarcinoma", "growth protocol: grown in DMEM/F12 (50/50) medium (Wisent), supplemented with 10 % fetal bovine serum and 2 mM L-glutamine, cells passaged as recommended by ATCC", "treatment: Treated with siRNA targeting RBFOX2 (CACCUCCGCAGAAUGGAAU). Transfection was performed in suspension using Lipofectamine 2000 (Life technologies) according to the manufacturer’s protocol and 20 nM of siRNA (Sigma) for 48 hours.")